Amy L. Burroughs

Amy L. Burroughs (board member) discloses dealings in 2 companies, chiefly Terns Pharmaceuticals, Inc. and DiaMedica Therapeutics Inc. Between 16 August 2021 and 16 March 2026, the trades on record add up to 22 filings.

On the open market, the record shows 4 purchases worth €305k and 8 sales worth €5.6M. On balance, insiders were net sellers of €5.3M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 3 share grants and 7 option exercises. In 2026 alone, the filings show no purchases and 8 sales.

A typical purchase (the median) is worth €91k. On 3 out of 4 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 17 March 2026 with an open-market sale (€115k) in Terns Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 486 days ago, on 25 June 2025. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.